Opsoclonus-Myoclonus Syndrome

Opsoclonus-Myoclonus Syndrome

Introduction

Opsoclonus Myoclonus Syndrome is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Opsoclonus-Myoclonus Syndrome (OMS)[@denguetriggered], also known as Opsoclonus-Myoclonus-Ataxia (OMA) or "dancing eyes-dancing feet" syndrome, is a rare neuroimmune disorder[@hla] characterized by a triad of symptoms: opsoclonus (rapid, involuntary, multi-directional eye movements), myoclonus (sudden, involuntary muscle jerks), and ataxia (loss of coordination)[@denguetriggered]. This syndrome represents an important intersection ofautoimmunity, neuroinflammation, and neurodegeneration, with significant implications for understanding paraneoplastic neurological syndromes. [@hla]

Overview

Opsoclonus-Myoclonus Syndrome is a complex neurological disorder that can affect individuals of any age, though it most commonly presents in children between 1-4 years of age. In pediatric cases, OMS is frequently associated with underlying neuroblastoma[@case] (a neural crest tumor), earning it the classification as a paraneoplastic neurological syndrome. In adults, OMS may be associated with various malignancies including small cell lung cancer, breast cancer, or ovarian teratomas, or may occur without identifiable tumor association (idiopathic). [@case]

Opsoclonus-Myoclonus Syndrome

Introduction

Opsoclonus Myoclonus Syndrome is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Opsoclonus-Myoclonus Syndrome (OMS)[@denguetriggered], also known as Opsoclonus-Myoclonus-Ataxia (OMA) or "dancing eyes-dancing feet" syndrome, is a rare neuroimmune disorder[@hla] characterized by a triad of symptoms: opsoclonus (rapid, involuntary, multi-directional eye movements), myoclonus (sudden, involuntary muscle jerks), and ataxia (loss of coordination)[@denguetriggered]. This syndrome represents an important intersection ofautoimmunity, neuroinflammation, and neurodegeneration, with significant implications for understanding paraneoplastic neurological syndromes. [@hla]

Overview

Opsoclonus-Myoclonus Syndrome is a complex neurological disorder that can affect individuals of any age, though it most commonly presents in children between 1-4 years of age. In pediatric cases, OMS is frequently associated with underlying neuroblastoma[@case] (a neural crest tumor), earning it the classification as a paraneoplastic neurological syndrome. In adults, OMS may be associated with various malignancies including small cell lung cancer, breast cancer, or ovarian teratomas, or may occur without identifiable tumor association (idiopathic). [@case]

The syndrome is considered an autoimmune disorder[@prolonged] in which the immune system mistakenly attacks neural tissues, particularly in the cerebellum and brainstem regions responsible for motor control and eye movement coordination. This autoimmune attack leads to the characteristic neurological symptoms and can result in long-term cognitive and behavioral sequelae if not adequately treated. [@prolonged]

Epidemiology

OMS is a rare condition with an estimated annual incidence of approximately 0.27-0.5 cases per million[@opsoclonusmyoclonus] population in children. The peak incidence occurs in early childhood, with most cases diagnosed between 18 months and 3 years of age. There appears to be a slight female predominance in pediatric cases, with a female-to-male ratio of approximately 1.5:1. In adults, the syndrome is even rarer, with most cases reported in individuals between 20-50 years of age. [@opsoclonusmyoclonus]

Approximately 50-60% of pediatric OMS cases are associated with neuroblastoma, making it one of the most common paraneoplastic neurological syndromes in children. The remaining cases are classified as idiopathic or post-infectious in origin. In adults, approximately 20-30% of OMS cases are associated with underlying malignancies. [^6]

Pathophysiology

Immune-Mediated Mechanism

The pathogenesis of OMS involves a dysregulated immune response that targets neuronal antigens, particularly those expressed in the cerebellum, brainstem, and spinal cord. Several immune mechanisms have been implicated: [^7]

B-cell mediated autoimmunity: Patients with OMS produce autoantibodies against neuronal antigens. While no single specific antibody has been consistently identified, candidates include antibodies against: [^8]

• Cartilage-related antigen (CRMP5): Also known as CV2, this antibody is associated with paraneoplastic neurological syndromes
• Anti-neuronal nuclear antibodies (ANNA-1/anti-Hu): Associated with small cell lung cancer
• GAD65 antibodies: Glutamic acid decarboxylase, though less common in OMS
• Surface membrane antibodies: Including those targeting voltage-gated calcium channel subunits

Cytokine dysregulation: Elevated levels of pro-inflammatory cytokines including IL-6, TNF-α, and IFN-γ have been documented in OMS patients, indicating a systemic inflammatory component. [^10]

Tumor Association

In paraneoplastic OMS, the tumor expresses neuronal antigens that trigger an immune response. The immune system attacks both the tumor and the nervous system due to cross-reactivity (molecular mimicry). Neuroblastoma cells, which arise from sympathetic nervous system precursors, naturally express neural antigens that can trigger this cross-reactive immune response. [^11]

Clinical Presentation

Classic Triad

The hallmark symptoms of OMS include: [^12]

Opsoclonus: [^13]

• Rapid, involuntary, chaotic, multi-directional saccadic eye movements
• Occur continuously during waking hours
• Horizontal, vertical, and torsional components
• May be exacerbated by attempted fixation or eye-opening

• Sudden, brief, shock-like involuntary muscle contractions
• Typically affect limbs, trunk, and sometimes the face
• Can be focal or generalized
• Often worsen with voluntary movement or emotional stress

• Cerebellar gait instability
• Truncal instability and titubation
• Limb incoordination
• May be severe enough to prevent independent walking

Additional Neurological Features

Beyond the classic triad, patients may experience:

• Tremor: Intention tremor and postural tremor
• Dysmetria: Past-pointing on finger-to-nose testing
• Dysarthria: Slurred speech due to cerebellar involvement
• Nystagmus: Jerky nystagmus may accompany opsoclonus
• Cognitive and behavioral changes: Irritability, attention deficits, sleep disturbances
• Hypotonia: Decreased muscle tone is common in children

Systemic Features

In paraneoplastic cases, symptoms related to the underlying tumor may be present:

• Abdominal mass (neuroblastoma)
• Hypertension (catecholamine secretion from neuroblastoma)
• Systemic constitutional symptoms

Diagnosis

Clinical Criteria

Diagnosis of OMS is primarily clinical, based on recognition of the characteristic triad:

The presence of all three symptoms establishes the diagnosis. In incomplete presentations, two of three core features plus supporting evidence (paraneoplastic antibodies, tumor) can establish the diagnosis.

Diagnostic Workup

Neurological examination: Assessment of eye movements, coordination, gait, and muscle tone

Imaging studies:

• MRI brain and spine to rule out structural lesions
• May show cerebellar or brainstem T2 hyperintensities in acute phase
• Often normal in chronic/stable phases

• CSF analysis: May show mild pleocytosis or elevated protein
• Paraneoplastic antibody panel: Including anti-Hu, anti-Ri, anti-Yo, anti-CRMP5, anti-GAD
• Urine catecholamines: Elevated in neuroblastoma (HVA, VMA)

• Abdominal ultrasound and MRI to detect neuroblastoma
• CT chest and abdomen
• PET-CT for occult malignancies in adults

• EEG may show generalized slowing but is non-specific

Treatment

Immunotherapy

First-line treatment for OMS involves aggressive immunotherapy:

Corticosteroids: High-dose intravenous methylprednisolone pulses followed by oral prednisone taper

Intravenous immunoglobulin (IVIG): Modulates immune response, often used in combination with steroids

Rituximab: Anti-CD20 monoclonal antibody depletes B-cells, showing significant efficacy in steroid-dependent or refractory cases

Cyclophosphamide: Alkylating agent used in severe or refractory cases

Plasma exchange: May provide rapid improvement in acute severe cases

Tumor Resection

In paraneoplastic cases, tumor resection is crucial:

• Surgical removal of neuroblastoma when feasible
• May result in neurological improvement even without complete tumor resection
• Chemotherapy for metastatic neuroblastoma per pediatric oncology protocols

Supportive Management

• Physical and occupational therapy for motor rehabilitation
• Speech therapy for dysarthria
• Educational support for cognitive/behavioral issues
• Seizure prophylaxis if indicated

Treatment Protocol (Pediatric)

A typical treatment algorithm includes:

Prognosis

Long-Term Outcomes

With modern aggressive immunotherapy, prognosis has improved significantly:

Neurological recovery:

• Most patients achieve significant functional improvement
• Opsoclonus typically responds well to treatment
• Ataxia may persist in milder form
• Myoclonus often improves substantially

• Intelligence typically preserved
• Learning disabilities and attention deficits common
• Behavioral issues in 30-50% of children
• Sleep disturbances may persist

• Relapses occur in 30-50% of cases, often during immunotherapy taper
• Relapses typically respond to re-escalation of immunotherapy
• Long-term maintenance therapy may reduce relapse risk

Mortality

With appropriate treatment and tumor management, mortality is primarily related to the underlying malignancy rather than neurological complications. In idiopathic or non-paraneoplastic cases, prognosis is generally favorable with aggressive immunotherapy.

Research Directions

Biomarker Development

Current research focuses on:

• Identifying specific biomarkers for diagnosis and treatment response
• Characterizing autoantibody profiles
• Developing assays for early detection of relapse

Understanding Pathogenesis

• Elucidating the specific neuronal antigens targeted
• Understanding tumor-immune interactions
• Investigating genetic susceptibility factors
• Studying the role of B-cell and T-cell compartments

Treatment Optimization

• Comparing different immunotherapy regimens
• Identifying predictors of treatment response
• Developing targeted biologic therapies
• Understanding mechanisms of treatment resistance

Neuroimaging Studies

• Using advanced MRI techniques to characterize cerebellar involvement
• Functional imaging to understand network dysfunction
• PET studies of neuroinflammation

See Also

• [Paraneoplastic Neurological Syndromes](/diseases/paraneoplastic-syndromes)
• [Autoimmune Encephalitis](/diseases/autoimmune-encephalitis)
• [Cerebellar Ataxia](/mechanisms/cerebellar-degeneration)
• [Neuroblastoma](/diseases/neuroblastoma)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Paraneoplastic Cerebellar Degeneration](/cell-types/paraneoplastic-cerebellar-degeneration-neurons)
• [Anti-NMDA Receptor Encephalitis](/diseases/anti-nmda-receptor-encephalitis)

External Links

• [National Institute of Neurological Disorders and Stroke - OMS Information](https://www.ninds.nih.gov/Disorders/All-Disorders/Opsoclonus-Myoclonus-Syndrome-Information-Page)
• [Orphanet - Opsoclonus Myoclonus Syndrome](https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=97339)
• [Opsoclonus-Myoclonus Syndrome Foundation](https://www.omsusa.org/)
• [Cancer Research UK - Paraneoplastic Syndromes](https://www.cancerresearchuk.org/about-cancer/other-conditions/paraneoplastic-syndromes)

Background

The study of Opsoclonus Myoclonus Syndrome has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Dengue-triggered opsoclonus myoclonus ataxia syndrome in an infant.](https://pubmed.ncbi.nlm.nih.gov/41591956/) (2026 Apr) - Tropical doctor
• [HLA and T-Cell Receptor Investigations in Idiopathic and Paraneoplastic Opsoclonus-Myoclonus in Children.](https://pubmed.ncbi.nlm.nih.gov/41499722/) (2026 Mar) - Neurology(R) neuroimmunology & neuroinflammation
• [Case Report and Literature Review of Mycoplasma Pneumoniae Associated Opsoclonus-Myoclonus-Ataxia Syndrome.](https://pubmed.ncbi.nlm.nih.gov/41697567/) (2026 Feb 16) - Cerebellum (London, England)
• [Prolonged Diagnostic Latency and Long-term Surveillance in Anti-Ri Antibody-positive Opsoclonus-myoclonus Syndrome with Carcinoma of Unknown Primary.](https://pubmed.ncbi.nlm.nih.gov/41093557/) (2026 Feb 15) - Internal medicine (Tokyo, Japan)
• [Opsoclonus-myoclonus syndrome with anti-SOX1 antibodies.](https://pubmed.ncbi.nlm.nih.gov/41629114/) (2026 Feb 2) - BMJ case reports

References